During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Objective: The aim of the present study was to monitor the efficacy and tolerability of glimepiride in daily practice. Design: An 8-week non-interventional cohort study investigating glimepiride ...

Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

Preclinical in vivo data show that OKI-219 used in combination with standard-of-care therapies for mutant-selected solid tumors, including breast cancers, showed potent anti-tumor activity with ...

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, ...

In a previous study comparing the efficacy and tolerability of magnesium and sodium salts of valproic acid in 45 patients with various forms of epilepsy, Matera et al. [13] found an overall ...

A PDUFA date has been set for October 20, 2025. If approved, Epoxia will be the first epi-on corneal crosslinking on the market.

has proven efficacy and tolerability in migraine. In a prospective open-label study, Lampl and co-workers have shown this drug to have promise in the prophlyaxis of chronic tension-type headache.